A study published online in the Journal of Investigative Dermatology on 16 October 2026 concludes that EGFR activity governs fibrotic responses in recessive dystrophic epidermolysis bullosa — and that those responses shift depending on disease stage.

The paper, authored by Bing Hang and Alexander Nyström, positions epidermal growth factor receptor signaling not as a bystander but as a controlling factor in how fibrosis develops in RDEB, a severe inherited blistering disorder caused by loss-of-function variants in COL7A1.

Why stage-dependence matters in RDEB

Recessive dystrophic epidermolysis bullosa is marked by chronic wounds, scarring and aggressive fibrosis. The most feared complication in adults is squamous cell carcinoma, which arises in chronically fibrotic scar tissue and is a leading cause of death in this patient population.

The authors' central claim — that EGFR-driven fibrotic responses are stage-dependent — suggests the same molecular pathway may act differently early versus late in the disease course. That framing matters clinically: a pathway that drives useful early tissue repair could later fuel pathological scarring, or vice versa.

The study title identifies EGFR activity as the governing variable. In RDEB research, EGFR signaling has drawn attention because it regulates keratinocyte proliferation, migration and wound-edge behavior — processes that overlap with fibrogenic signaling from dermal fibroblasts and myofibroblasts.

What does this change for RDEB therapy?

The practical question for clinicians: could existing EGFR inhibitors — several are already approved in oncology — be repurposed to blunt fibrosis in RDEB?

The stage-dependence finding is the key caveat. If EGFR activity produces different fibrotic outcomes at different disease stages, timing of any intervention becomes critical. Blocking EGFR too early could impair re-epithelialization of wounds; targeting it later might curb the fibrosis that sets the stage for SCC.

Nystöm's group has built its reputation on dissecting fibrotic mechanisms in epidermolysis bullosa, and this paper extends that program into pathway-stage mapping rather than a single-target model.

The study appeared online on 16 October 2026. Derm Field will follow the full text for effect sizes, model systems and any dosing data as the print version releases.